UWCCC Molecular Tumor Board Registry

NCT03023202 — Recruiting, 10000 participants, University of Wisconsin, Madison

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

UWCCC Precision Medicine Molecular Tumor Board Registry

Registry	NCT03023202
Status	Recruiting
Study type	Observational
Enrollment	10000 (Estimated)
Sponsor	University of Wisconsin, Madison (Other); collaborators: National Cancer Institute (NCI)
Conditions	Hematologic Neoplasms, Solid Neoplasm
Interventions	PMMTB (Precision Medicine Molecular Tumor Board) (Other)
Dates	start 2016-03-30, primary completion 2029-03-01 (estimated), completion 2029-03-01 (estimated), first posted 2017-01-18, last updated 2026-04-13
Locations	1 site in United States

-Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
PMMTB		Other: PMMTB (Precision Medicine Molecular Tumor Board)	This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.

PMMTB (Precision Medicine Molecular Tumor Board) (Other): PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

+Outcome measures

Primary outcomes

Frequency of acceptance of molecular tumor board recommendations [Up to 5 years]: How often the molecular tumor board's recommendations are accepted
Benefit from PMMTB recommended treatment [Up to 5 years]: Whether patients benefit from PMMTB recommended treatment

Secondary outcomes

Correlation of mutations with protein overexpression [Up to 5 years]: Correlate mutations identified in tumor tissue with protein overexpression
Correlations of mutations with circulating tumor DNA [Up to 5 years]: Correlate mutations identified in tumor tissue with circulating tumor DNA
Correlations of mutations with spheroid culture investigations [Up to 5 years]: Correlate mutations identified in tumor tissue with spheroid culture investigations

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Clinically suspected or histologically confirmed solid or hematological malignancy
* Undergoing genetic testing of tumor
* Ability to understand written informed consent document
* Willingness to sign written informed consent document

Exclusion Criteria:

* Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

+Locations (1)

Facility	City	Country	Status
University of Wisconsin Carbone Cancer Center	Madison, Wisconsin	United States	Recruiting

+Investigators

Dustin Deming, MD, Principal investigator, University of Wisconsin, Madison

+Funding

NIH grants: P30CA014520, R37CA226526